Source link : https://www.newshealth.biz/health-news/tirzepatide-officially-off-fdas-shortage-list/
The shortage of the diabetes and obesity injectable tirzepatide (Mounjaro, Zepbound) has been resolved, the FDA announced Thursday. As a result, compounders will have a grace period of 60 to 90 days to wrap up production and distribution of the combination GIP/GLP-1 receptor agonist during which the FDA won’t take legal action against them, “to […]
Author : News Health
Publish date : 2024-12-19 17:48:23
Copyright for syndicated content belongs to the linked Source.